Does Medicare Cover CGMs (Dexcom/Libre) in 2026?

Full answer: Yes. Medicare Part B covers continuous glucose monitors (CGM) as durable medical equipment for beneficiaries with diabetes who use insulin or have a documented history of problematic hypoglycemia, under CMS's April 2023 coverage expansion. Covered systems include the Dexcom G6, Dexcom G7, FreeStyle Libre 2, FreeStyle Libre 3, and the Eversense implantable CGM. You pay 20% of the Medicare-approved amount after the 2026 Part B deductible of $283, and Medicare Advantage plans must match this benefit at minimum.

Continuous glucose monitors changed diabetes management by replacing painful fingerstick checks with a sensor that tracks blood sugar every few minutes, and Medicare recognized that value years ago. Original Medicare Part B has covered CGMs since 2017, and a major CMS policy expansion effective April 16, 2023 opened coverage to millions more beneficiaries who do not use insulin but struggle with dangerous low blood sugar episodes.

Whether Dexcom or FreeStyle Libre coverage applies to you depends on your diabetes treatment, your hypoglycemia history, and a few documentation rules that trip up otherwise-eligible beneficiaries. This guide covers the 2026 eligibility criteria, what Original Medicare and Medicare Advantage each pay, cash-pay pricing if you do not qualify, and the exact steps to get a CGM ordered. For related diabetes coverage, see does Medicare cover insulin. To confirm your broader Medicare eligibility, use the CoveredUSA screener.

Coverage Breakdown

Coverage by type
Coverage Source	CGM Covered	2026 Cost to You	Key Conditions
Original Medicare Part B	Yes	20% of the Medicare-approved amount after the 2026 Part B deductible of $283	Must use insulin or have documented problematic hypoglycemia; device must support a standalone receiver
Medicare Advantage (Part C)	Yes	Same 20% coinsurance minimum; many plans offer $0 copay for Dexcom or Libre supplies	Must meet Original Medicare's minimum criteria; some plans require prior authorization
Medigap (Medicare Supplement)	Partial (coinsurance only)	Covers the 20% Part B coinsurance for CGM supplies after the deductible is met	Does not add devices Original Medicare denies; supplements Part B cost-sharing only
Cash pay / manufacturer programs	Not insurance	$70 to $350 per month retail depending on device; savings programs from $35 to $89 per month	For beneficiaries who do not yet meet Medicare's criteria or need backup supply

Medicare CGM coverage by plan type 2026: CMS expanded eligibility on April 16, 2023 (National Coverage Determination 40.5 and DME MAC Policy Article A52464) to include non-insulin-treated beneficiaries with a documented history of problematic hypoglycemia, not just insulin users.

Source: Medicare.gov Continuous Glucose Monitors, CMS DME MAC Policy Article A52464, CMS National Coverage Determination 40.5

Direct Answer: Medicare CGM Coverage in 2026

Yes. Medicare Part B covers continuous glucose monitors as durable medical equipment for beneficiaries with diabetes who use insulin or have a documented history of problematic hypoglycemia, per CMS's April 2023 coverage expansion. Covered systems include Dexcom G6, G7, FreeStyle Libre 2, Libre 3, and Eversense. You pay 20% of the Medicare-approved amount after the 2026 Part B deductible of $283, and Medicare Advantage plans must match this benefit at minimum.

What Original Medicare Part B Covers for CGMs (2026)

Original Medicare classifies a therapeutic CGM system as durable medical equipment (DME) rather than a prescription drug, so it is billed under Part B, not Medicare Part D (the pharmacy drug benefit that covers insulin filled at a retail pharmacy). Coverage includes the CGM receiver or transmitter, sensors, and related supplies, at 80 percent of the Medicare-approved amount once you have met the 2026 Part B deductible of $283. Medicare Part A does not cover outpatient CGM supplies at all; Part A's role is limited to diabetes self-management training furnished during an inpatient hospital stay.

Medicare requires a therapeutic CGM, meaning the device is approved to make treatment decisions (dosing insulin, adjusting food intake) without a confirmatory fingerstick test. Dexcom G6, Dexcom G7, FreeStyle Libre 2, FreeStyle Libre 3, and the Eversense implantable CGM all meet this standard and are covered nationwide when the DME supplier is enrolled in Medicare and bills correctly.

Who Qualifies: The 2023 CGM Eligibility Expansion

CMS finalized a major eligibility expansion effective April 16, 2023 that removed the old requirement of multiple daily insulin injections. Two pathways now qualify a beneficiary for CGM coverage in 2026. Pathway one covers anyone treated with insulin, regardless of type or how much they take. Pathway two covers beneficiaries not on insulin who have a documented history of problematic hypoglycemia, defined as more than one Level 2 hypoglycemic event (glucose under 54 mg/dL) despite treatment changes, or one Level 3 event severe enough to require third-party assistance.

Documentation matters as much as the medical facts. Your treating practitioner must have seen you in person or through a Medicare-approved telehealth visit within the 6 months before ordering the CGM, and must document in your medical record that you have diabetes, meet one of the two pathways above, and have received training on using the device correctly. Every 6 months after that, a follow-up visit is required to justify continued coverage.

Device Requirements: The Standalone Receiver Rule

Medicare only pays for CGM supplies when the system can display glucose readings on a stand-alone receiver or an insulin pump classified as DME, not solely on a smartphone or tablet. Dexcom G6 and Dexcom G7 supplies are not covered when used only with a smartphone app; you (or your DME supplier) must also obtain the compatible standalone receiver to meet Medicare's DME definition, even if you primarily view readings on your phone day to day.

Dexcom G6 and G7: requires the Dexcom receiver in addition to (or instead of) the smartphone app to bill Medicare.
FreeStyle Libre 2 and Libre 3: the Libre reader device satisfies the standalone requirement; the phone app can be used alongside it.
Eversense implantable CGM: the transmitter and smart transmitter combination satisfies DME classification for the 6-month or 1-year sensor.

You may qualify for free health insurance.

Our 2-minute screener checks Medicaid, ACA, Medicare, CHIP, and more. Most uninsured Americans qualify for $0/month coverage they didn't know about.

Check what I qualify for — free

What Medicare Advantage May Add for CGM Coverage (2026)

Medicare Advantage plans must cover CGMs to at least the same standard as Original Medicare, since Part C plans cannot offer less than Part A and Part B combined. In practice, many Medicare Advantage plans go further in 2026 by waiving the 20 percent coinsurance entirely for in-network DME suppliers, offering $0 copay CGM supplies as a supplemental benefit, or bundling CGM management into a broader diabetes care program with a care coordinator. Some plans add prior authorization requirements Original Medicare does not have, so check your plan's Evidence of Coverage before ordering.

Cost of a CGM Without Medicare Coverage in 2026

Full retail pricing in 2026 runs about $350 per month for Dexcom G7 (roughly $175 per sensor box) and about $70 per month for FreeStyle Libre 3 (roughly $35 per sensor), before any manufacturer discount. Beneficiaries who do not yet meet Medicare's insulin-use or problematic-hypoglycemia criteria, or who want backup sensors between Medicare-covered supply shipments, often pay these cash-pay rates directly to the manufacturer or pharmacy.

Manufacturer savings programs cut those cash prices substantially in 2026. Dexcom's Simple Start program prices G7 supplies as low as $89 per month for uninsured patients, and Abbott's MyFreeStyle savings program lowers Libre 3 cash pricing for patients who do not have Medicare or other insurance covering the device. Neither program is insurance and neither counts toward Medicare's 2026 Part B deductible or the annual out-of-pocket cost of your Medicare plan.

Dual-Eligible Beneficiaries: Medicare and Medicaid Together

About 12 million Americans are dual-eligible for Medicare and Medicaid. For CGM supplies, Medicare Part B pays first as the primary payer at 80 percent of the approved amount, and Medicaid, as the secondary payer, typically picks up the remaining 20 percent coinsurance and the Part B deductible in full, meaning most dual-eligible beneficiaries pay nothing out of pocket for a Medicare-covered CGM. Medicaid programs in every state also cover CGMs independently for enrollees who do not yet have Medicare, though income limits, prior authorization rules, and covered brands vary by state.

Not Yet on Medicare? ACA Marketplace CGM Coverage

Diabetes management devices fall under the ACA's essential health benefit category for rehabilitative and habilitative devices, so ACA-compliant marketplace plans generally must cover CGMs when medically necessary, though formularies, tiers, and prior authorization rules vary by insurer and state. ACA plans cannot deny CGM coverage based on a preexisting condition such as diabetes, unlike pre-2014 individual market plans. If you are approaching age 65, coordinate the switch from marketplace coverage to Medicare during your Initial Enrollment Period to avoid a coverage gap for your CGM supplies.

Frequently Asked Questions

Does Original Medicare cover the Dexcom G7?

Yes. Original Medicare Part B covers the Dexcom G7 as durable medical equipment for beneficiaries who use insulin or have a documented history of problematic hypoglycemia. You pay 20% of the Medicare-approved amount after the 2026 Part B deductible of $283. The G6 and G7 both require a compatible standalone receiver on file with your supplier; smartphone-only use is not billable to Medicare.

Does Medicare cover FreeStyle Libre 2 or Libre 3?

Yes. Medicare Part B covers FreeStyle Libre 2 and Libre 3 for beneficiaries meeting the insulin-use or problematic-hypoglycemia criteria. The Libre reader device satisfies Medicare's standalone-receiver requirement, so you can use the reader alongside the LibreLink phone app without a separate receiver purchase, unlike some Dexcom setups.

What are Medicare's CGM eligibility requirements in 2026?

You qualify if you have diabetes and either use insulin (any type or amount) or have a documented history of problematic hypoglycemia, defined as more than one Level 2 event (glucose under 54 mg/dL) or one Level 3 event requiring third-party assistance. Your practitioner must also see you within 6 months before ordering the CGM and document your training on the device, per the CMS coverage expansion effective April 16, 2023.

Does Medicare Advantage cover CGMs?

Yes. Medicare Advantage plans must cover CGMs at least as well as Original Medicare, and many 2026 plans offer $0 copay CGM supplies through in-network DME suppliers as an added benefit. Some Medicare Advantage plans add prior authorization steps Original Medicare does not require, so check your plan's Evidence of Coverage before ordering.

How much does a CGM cost without Medicare coverage in 2026?

Full retail runs about $350 per month for Dexcom G7 and about $70 per month for FreeStyle Libre 3 in 2026. Manufacturer savings programs lower 2026 cash pricing substantially: Dexcom's Simple Start program prices G7 supplies as low as $89 per month for uninsured patients, and Abbott's MyFreeStyle program discounts Libre 3 for patients without CGM insurance coverage.

Does Medicare cover a CGM for type 2 diabetes if I am not on insulin?

Yes, if you have a documented history of problematic hypoglycemia. Since CMS's April 2023 expansion, beneficiaries with type 2 diabetes who are not insulin-treated qualify when they have had more than one Level 2 hypoglycemic event despite treatment changes, or one Level 3 event requiring assistance from another person. Insulin use is no longer required for CGM coverage.

Can I use a smartphone-only CGM setup with Medicare?

Not for billing purposes. Medicare requires the CGM system to display readings on a standalone receiver or an insulin pump classified as durable medical equipment. Dexcom G6 and G7 supplies are not covered when used only with a smartphone app; you need the compatible standalone receiver on file even if you check readings mostly on your phone.

What if Medicare denies my CGM claim?

Most CGM denials trace back to missing documentation: no record of insulin use or problematic hypoglycemia, no practitioner visit within 6 months of the order, or no standalone receiver on file. Ask your practitioner to resubmit with complete documentation, or file a Medicare appeal within 120 days of the denial notice. Your DME supplier can often identify the specific missing item before you appeal.